BrightFocus Foundation Awards Nearly $13M to 50 Scientists for Alzheimer's, Macular Degeneration, and Glaucoma Research
CLARKSBURG, Md.--(BUSINESS WIRE)--Private research nonprofit BrightFocus Foundation today announced nearly $13 million in grants to support early investigative research into Alzheimer's disease, macular degeneration, and glaucoma. This includes $7.3 million to its Alzheimer's Disease Research program, $3.8 million to its Macular Degeneration Research program, and $1.8 million to its National Glaucoma Research program.
'With recent major cuts to federal research funding, private foundations like BrightFocus are more essential than ever—stepping up to keep promising research alive, nurture early-career scientists, and accelerate breakthroughs.'
Share
Guided by scientific advisory committees of world-renowned researchers in the field, BrightFocus invests in highly innovative, experimental research and creative ideas with the most promise to foster a better understanding of disease onset, improve early detection and diagnosis, develop new treatments, and—ultimately—lead to cures. This year's grants were awarded to scientists in 10 countries including the U.S.
'This year's grant awards represent some of the boldest, most cutting-edge ideas in vision and brain health research,' said BrightFocus President and CEO Stacy Pagos Haller. 'With recent major cuts to federal research funding, private foundations like BrightFocus are more essential than ever—stepping up to keep promising research alive, nurture early-career scientists, and accelerate breakthroughs.'
BrightFocus Foundation's research programs are supported entirely by private donor contributions from the public and corporate and foundation grants; BrightFocus receives no government funding. Learn more about how to support our work.
A complete list of the new research projects will be available this summer on BrightFocus' website, with additional details forthcoming upon the completion of individual agreements with the partnering institutions and scientists.
Alzheimer's Disease Research
Over 7 million Americans aged 65 and older are living with Alzheimer's disease, a progressive, terminal brain disorder that has no known cause or cure. Unless scientists can unlock the secrets of this disease, the number of cases is expected to triple by the year 2050. Grant recipients are studying a range of approaches spanning different areas of the brain and body to better understand the disease's onset and progression.
Alzheimer's Disease Research grant recipients:
Katerina Akassoglou, PhD
The J. David Gladstone Institutes
Federica Anastasi, PhD
Barcelonaβeta Brain Research Center (Spain)
Isabelle Aubert, PhD
Sunnybrook Research Institute (Canada)
Daniel Bos, MD, PhD
Erasmus University Medical Center Rotterdam (Netherlands)
Todd J. Cohen, PhD
University of North Carolina at Chapel Hill
Joshua Emmerson, PhD
Washington University in St. Louis
Ghazaleh Eskandari-Sedighi, PhD
University of California, Irvine
Anllely Fernandez, PhD
Indiana University
Hongjun Fu, PhD
The Ohio State University
Laura Fumagalli, PhD
Flanders Institute for Biotechnology (Belgium)
John Hardy, PhD, FRS
University College London (U.K.)
Joseph Herdy, PhD
The Salk Institute for Biological Studies
Sarah Elise Heuer, PhD
Brigham and Women's Hospital
Jack Humphrey, PhD
Icahn School of Medicine at Mount Sinai
Ksenia Kastanenka, PhD
Massachusetts General Hospital
Jr-Jiun Liou, PhD
University of Pittsburgh
Jae-eun Miller, PhD
Columbia University
Miguel Moutinho, PharmD, PhD
Indiana University
Carolina Ochoa-Rosales, PhD
Adolfo Ibáñez University (Chile)
Omar Peña-Ramos, PhD
Baylor College of Medicine
Cyril Pottier, PhD
Washington University in St. Louis
Marcos Schaan Profes, PhD
Icahn School of Medicine at Mount Sinai
Nader Saffari, PhD, MSc, BSc
University College London (U.K.)
Monica Santisteban, PhD
Vanderbilt University Medical Center
Feng Tian, PhD
Beth Israel Deaconess Medical Center
Rebecca Wallings, DPhil
Indiana University
Justyna Dobrowolska Zakaria, PhD
Northwestern University - Chicago Campus
Damian Zuloaga, PhD
University at Albany
Macular Degeneration Research
Twenty million U.S. adults have macular degeneration—the leading cause of vision loss in Americans aged 65 and older. Early detection and treatment are crucial to slowing the disease progression and preventing permanent vision loss. Grant recipients are exploring a wide range of innovative scientific approaches, from exploring ways to regenerate damaged cells to determining the influence of early-life events and lifestyle factors on disease risk.
Macular Degeneration Research grant recipients:
Mohajeet Balveer Bhuckory, PhD
Stanford University School of Medicine
Ana J. Chucair-Elliott, PhD
University of Oklahoma Health Sciences Center
Charles DeBoer, MD, PhD
Stanford University School of Medicine
Ashley Farre, PhD
University of Idaho
Valencia Fernandes, PhD
University of California, San Francisco
Masayuki Hata, MD, PhD
Kyoto University (Japan)
Ruchi Sharma, PhD
National Eye Institute, NIH
Nobuhiko Shiraki, PhD
Duke University School of Medicine
Daisy Yao Shu, PhD
University of New South Wales (Australia)
Jerzy Szablowski, PhD
William Marsh Rice University
Amir Mani Varnoosfaderani, PhD
University of Chicago
Joëlle Elise Vergroesen, PhD
Erasmus University Medical Center Rotterdam (Netherlands)
National Glaucoma Research
Around 4 million U.S. adults have glaucoma—a leading cause of blindness in the U.S. caused by damage to the optic nerve. Because there are often no early symptoms, as many as half of those affected may not even know they have it until irreversible vision loss has occurred. Although there is no cure, early detection and treatments can help slow the disease's progression.
Grant recipients are investigating a wide range of scientific approaches, including novel treatments, early detection methods, and efforts to protect and regenerate retinal ganglion cells that could preserve or restore vision.
National Glaucoma Research grant recipients:
Brad Fortune, OD, PhD
Legacy Research Institute
Tatjana Jakobs, MD
Schepens Eye Research Institute of Mass. Eye and Ear
Colleen McDowell, PhD
University of Wisconsin-Madison
Rob Nickells, PhD
University of Wisconsin-Madison
Gavin Roddy, MD, PhD
Mayo Clinic, Rochester
Dorota Skowronska-Krawczyk, PhD
University of California, Irvine
Dan Stamer, PhD
Duke University
Karl Wahlin, PhD
University of California, San Diego – Health Sciences
Pete Williams, PhD
Karolinska Institute (Sweden)
Benjamin Xu, MD, PhD
University of Southern California
BrightFocus encourages researchers with groundbreaking ideas to apply for a 2026 grant. Application information is available at brightfocus.org/apply.
About BrightFocus Foundation
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer's, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer's Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded over $300 million in groundbreaking research funding since its inception in 1973 and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Elion Launches Integration of Coalition for Health AI ‘Nutrition Label' Within Vendor Marketplace
NEW YORK--(BUSINESS WIRE)--Elion, the healthcare technology research and intelligence platform for the AI era, announced today a new partnership with the Coalition for Health AI (CHAI), an industry-led coalition committed to developing industry best practices and frameworks to further innovation, safety and security for health AI. As part of this partnership, Elion is beta-launching a new feature: Abridged CHAI model cards now appear on select vendor profiles across its platform. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly." To facilitate robust evaluation and accelerate adoption of successful AI solutions, CHAI developed an Applied Model Card framework, and recently established its first Model Card registry to support the rapid growth of model cards, or 'nutrition labels' for health AI, used to simplify procurement among health systems and solution providers. CHAI's model cards have created a more standard way to present foundational information about AI solutions, moving from powerpoint presentations to evidence and value-based procurement. Elion cofounder and CEO, Bobby Guelich, announced this new functionality at the CHAI Innovation Summit this week. Providing availability of CHAI's Model Cards through the Elion platform helps provider organizations quickly assess an AI model's intended use, oversight processes, and key performance considerations—all in the context of Elion's broader research and marketplace infrastructure. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly,' said Guelich. 'CHAI's work in this area is foundational, and we're excited to bring their model cards into the day-to-day workflows of technology decision-makers through Elion's marketplace.' This integration represents the latest step in Elion's mission to equip health systems with the data, tools, and guidance needed to evaluate and implement emerging technologies. The current version includes model cards for a limited set of vendor solutions, with broader availability planned later this year. 'I am thrilled to see our health AI nutrition label advancing effective and responsible health AI,' said Brian Anderson, CHAI's CEO. 'By integrating this with Elion, we are enabling health system AI solution evaluation and allowing decision-makers to easily access Model Cards. CHAI is driven by the expertise of our members and the feedback of our broader health ecosystem and the public. We look forward to working together to unlock the potential benefits of AI, on a foundation of trust, safety, and security." CHAI model cards were designed to enhance transparency and accountability across the AI lifecycle. By displaying key elements of these cards on vendor profiles, Elion aims to bridge the gap between technical documentation and real-world procurement. Learn more about CHAI model cards here. About Elion: Elion is a trusted health IT marketplace and research firm dedicated to empowering healthcare organizations through technology insights and strategic guidance. By bridging the gap between healthcare leaders and innovative solutions, Elion is driving the future of healthcare delivery. For more information, visit: About CHAI: The CHAI (Coalition for Health AI) mission is to be the trusted source of guidelines for Responsible AI in Health. It aims to ensure high-quality care, foster trust among users, and meet the growing healthcare needs. As a coalition bringing together leaders and experts representing health systems, startups, government and patient advocates, CHAI has established working groups focusing on privacy and security, fairness, transparency, usefulness, and safety of AI algorithms.
Yahoo
an hour ago
- Yahoo
MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics
— Milestone Achieved Through Growing Clinical Evidence Demonstrating Real-World Impact on Infection Management — — MeMed and Physicians Premier Celebrated Milestone Event in Corpus Christi, Texas — ANDOVER, Mass. & HAIFA, Israel, June 05, 2025--(BUSINESS WIRE)--MeMed, a global leader in host-response diagnostics, today announced a major milestone: more than 100,000 patients have now been tested with MeMed BV®, the company's flagship diagnostic that accurately distinguishes between bacterial and viral infections in just 15 minutes, based on the body's immune response. This milestone highlights MeMed's commitment to advancing precision medicine, empowering responsible antibiotic use by care providers, and transforming infection management across diverse care settings. Advancing Antibiotic Stewardship and Clinical Decision-Making The growing adoption of MeMed BV in emergency medicine, urgent care, and hospital settings indicates the industry's move toward host-response and precision diagnostics. From hospital systems to decentralized care providers, MeMed BV has been integrated into real-world clinical workflows by clinicians committed to improving patient outcomes. Among these trailblazing partners is Physicians Premier, an innovative network of freestanding emergency rooms that has embraced MeMed BV as part of its commitment to advanced, patient-centered care. The 100,000th patient test was performed at Physicians Premier's Parkdale clinic in Corpus Christi, Texas, a symbolic moment that was marked with a joint celebration between MeMed and Physicians Premier leadership earlier today. "At Physicians Premier, we are committed to delivering cutting edge, personalized care that prioritizes both patient well-being and best practices," said Teri Cardenas, CEO of Physicians Premier. "MeMed BV has empowered our clinicians to make more informed decisions, reducing unnecessary antibiotic prescriptions while improving patient outcomes. We are proud to stand with MeMed at the forefront of diagnostic innovation." Scaling Global Impact through Strategic Partnerships The 100,000-test milestone represents broader industry shifts toward rapid host-response diagnostics and underscores MeMed's global growth strategy. The company remains focused on scaling through partnerships with decentralized and hospital-based providers, integrating high-throughput analyzers to serve acute care settings, and collaborating on distribution agreements across the U.S., Europe, and emerging markets. "Crossing the 100,000-patient mark is more than a milestone—it's a meaningful indicator of the clinical value we're delivering," said Eran Eden, Ph.D., Co-Founder and CEO of MeMed. "It reflects the trust of a growing network of forward-thinking healthcare partners like Physicians Premier, as we jointly transform the landscape of infectious disease management. With only a fraction of the potential market reached—and backed by strong clinical evidence and strategic partnerships—we anticipate accelerating momentum, bringing critical answers to clinicians and patients when they matter most." MeMed continues to engage healthcare providers and industry leaders to advance adoption of rapid, reliable diagnostics that improve patient care. About MeMed At MeMed, our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. MeMed BV® is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes. MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to aid early risk assessment in ED patients with suspected infection or sepsis. It predicts severe outcomes within 72 hours and mortality within 14 days. MeMed Severity is not yet cleared for sale in any territory. Follow and connect with MeMed via LinkedIn, Twitter/X, and Facebook. View source version on Contacts MeMed Contact: Tal AvzizVice President, Global Marketingpr@ Media Relations Contact: Charya Wickremasinghe, Solutions LLCcwickremasinghe@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
MeMed BV Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics
ANDOVER, Mass. & HAIFA, Israel--(BUSINESS WIRE)--MeMed, a global leader in host-response diagnostics, today announced a major milestone: more than 100,000 patients have now been tested with MeMed BV ®, the company's flagship diagnostic that accurately distinguishes between bacterial and viral infections in just 15 minutes, based on the body's immune response. This milestone highlights MeMed's commitment to advancing precision medicine, empowering responsible antibiotic use by care providers, and transforming infection management across diverse care settings. @memeddx Surpasses 100,000 Patient Tests, Underscoring Adoption of Rapid Host-Response Diagnostics Share Advancing Antibiotic Stewardship and Clinical Decision-Making The growing adoption of MeMed BV in emergency medicine, urgent care, and hospital settings indicates the industry's move toward host-response and precision diagnostics. From hospital systems to decentralized care providers, MeMed BV has been integrated into real-world clinical workflows by clinicians committed to improving patient outcomes. Among these trailblazing partners is Physicians Premier, an innovative network of freestanding emergency rooms that has embraced MeMed BV as part of its commitment to advanced, patient-centered care. The 100,000th patient test was performed at Physicians Premier's Parkdale clinic in Corpus Christi, Texas, a symbolic moment that was marked with a joint celebration between MeMed and Physicians Premier leadership earlier today. 'At Physicians Premier, we are committed to delivering cutting edge, personalized care that prioritizes both patient well-being and best practices,' said Teri Cardenas, CEO of Physicians Premier. 'MeMed BV has empowered our clinicians to make more informed decisions, reducing unnecessary antibiotic prescriptions while improving patient outcomes. We are proud to stand with MeMed at the forefront of diagnostic innovation.' Scaling Global Impact through Strategic Partnerships The 100,000-test milestone represents broader industry shifts toward rapid host-response diagnostics and underscores MeMed's global growth strategy. The company remains focused on scaling through partnerships with decentralized and hospital-based providers, integrating high-throughput analyzers to serve acute care settings, and collaborating on distribution agreements across the U.S., Europe, and emerging markets. 'Crossing the 100,000-patient mark is more than a milestone—it's a meaningful indicator of the clinical value we're delivering,' said Eran Eden, Ph.D., Co-Founder and CEO of MeMed. 'It reflects the trust of a growing network of forward-thinking healthcare partners like Physicians Premier, as we jointly transform the landscape of infectious disease management. With only a fraction of the potential market reached—and backed by strong clinical evidence and strategic partnerships—we anticipate accelerating momentum, bringing critical answers to clinicians and patients when they matter most.' MeMed continues to engage healthcare providers and industry leaders to advance adoption of rapid, reliable diagnostics that improve patient care. About MeMed At MeMed, our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. MeMed BV ® is the first FDA-cleared host-immune response test for accurately distinguishing between bacterial and viral infections in 15 minutes. MeMed Severity ™ has received FDA Breakthrough Device Designation as a host-response test designed to aid early risk assessment in ED patients with suspected infection or sepsis. It predicts severe outcomes within 72 hours and mortality within 14 days. MeMed Severity is not yet cleared for sale in any territory. Follow and connect with MeMed via LinkedIn, Twitter/X, and Facebook.
